Liposomes for targeted delivery of antithrombotic drugs

Bibliography

• O'Reilly RA. Anticoagulants, antithrombotic, and thrombolytic drugs. In: Goodman LS, Gilman AG, Rall TW, Murad F, editors. Goodman & Gilman's the Pharmacological Basis of Therapeutics, 7th edition. New York: McGraw-Hill; 1985. p. 1338-59
   Google Scholar
• Beers MH, Berkow R. The Merck Manual, 7th edition. Whitehouse Station, NJ: Merck Research Laboratories, 1999
   Google Scholar
• Brandt JT. Overview of hemostasis. In: McClatchey KD, editor. Clinical Laboratory Medicine, 2nd edition. Baltimore, MD: Lippincott Williams & Wilkins; 2002. p. 987-1009
   Google Scholar
• Pierce TB, Razzuk MA, Razzuk LM, Hoover SJ. A comprehensive review of the physiology of hemostasis and antithrombotic agents. BUMC Proceedings 1999;12(1):39-49
   Google Scholar
• Julien RM. Drugs and the body. New York, NY: WH Freeman, 1987
   Google Scholar
• Furie B, Furie BC. Thrombus formation in vivo. J Clin Invest 2005;115(12):3355-62
   PubMed Web of Science ®Google Scholar
• Furie B, Furie BC. The molecular basis of blood coagulation. Cell 1988;53(4):505-18
   PubMed Web of Science ®Google Scholar
• Lijnen HR, Collen D. Molecular mechanism of fibrinolysis. Adv Exp Med Biol 1984;164:217-28
   PubMedGoogle Scholar
• Thorsen S. The mechanism of plasminogen activation and the variability of the fibrin effector during tissue-type plasminogen activator-mediated fibrinolysis. Ann NY Acad Sci 1992;667:52-63
   PubMed Web of Science ®Google Scholar
• Gaspard KJ. Disorders of haemostasis. In: Porth CM, editor. Pathophysiology: concepts of altered health states, 7th edition. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 287-98
   Google Scholar
• Dobrovolsky AB, Titaeva EV. The fibrinolysis system: regulation of activity and physiologic functions of its main components. Biochemistry (Mosc) 2002;67(1):99-108
   PubMed Web of Science ®Google Scholar
• Collen D. Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy. J Cell Biochem 1987;33(2):77-86
   PubMed Web of Science ®Google Scholar
• Mureebe L. Direct thrombin inhibitors: alternatives to heparin. Vascular 2007;15(6):372-5
   PubMed Web of Science ®Google Scholar
• Jagroop IA, Milionis HJ, Mikhailidis DP. Mechanism underlying increased platelet reactivity in patients with peripheral arterial disease. Int Angiol 1999;18(4):348-51
   PubMed Web of Science ®Google Scholar
• Hirsh J. Heparin. N Engl J Med 1991;324(22):1565-74
   PubMed Web of Science ®Google Scholar
• Byun Y, Yang VC. Delivery system for targeted thrombolysis without the risk of hemorrhage. Asaio J 1998;44(5):M638-41
   PubMed Web of Science ®Google Scholar
• Marder VJ, Landskroner K, Novokhatny V, et al. Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit. Thromb Haemost 2001;86(3):739-45
   PubMed Web of Science ®Google Scholar
• Novokhatny V, Taylor K, Zimmerman TP. Thrombolytic potency of acid-stabilized plasmin: superiority over tissue-type plasminogen activator in an in vitro model of catheter-assisted thrombolysis. J Thromb Haemost 2003;1(5):1034-41
   PubMed Web of Science ®Google Scholar
• Collins R, Peto R, Baigent C, Sleight P. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med 1997;336(12):847-60
   PubMed Web of Science ®Google Scholar
• Zijlstra F, Hoorntje JC, de Boer MJ, et al. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1999;341(19):1413-9
   PubMed Web of Science ®Google Scholar
• Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333(24):1581-7
   PubMed Web of Science ®Google Scholar
• Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke 1997;28(11):2109-18
   PubMed Web of Science ®Google Scholar
• Larrue V, von Kummer R, del Zoppo G, Bluhmki E. Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study. Stroke 1997;28(5):957-60
   PubMed Web of Science ®Google Scholar
• Lansberg MG, Albers GW, Wijman CA. Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors. Cerebrovasc Dis 2007;24(1):1-10
   PubMed Web of Science ®Google Scholar
• Lapchak PA, Chapman DF, Zivin JA. Pharmacological effects of the spin trap agents N-t-butyl-phenylnitrone (PBN) and 2,2,6,6-tetramethylpiperidine-N-oxyl (TEMPO) in a rabbit thromboembolic stroke model: combination studies with the thrombolytic tissue plasminogen activator. Stroke 2001;32(1):147-53
   PubMed Web of Science ®Google Scholar
• Asahi M, Asahi K, Wang X, Lo EH. Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats. J Cereb Blood Flow Metab 2000;20(3):452-7
   PubMed Web of Science ®Google Scholar
• Wang X, Tsuji K, Lee SR, et al. Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke 2004;35(11 Suppl 1):2726-30
   PubMed Web of Science ®Google Scholar
• Asahi M, Rammohan R, Sumii T, et al. Antiactin-targeted immunoliposomes ameliorate tissue plasminogen activator-induced hemorrhage after focal embolic stroke. J Cereb Blood Flow Metab 2003;23(8):895-9
   PubMed Web of Science ®Google Scholar
• Armstrong PW, Antman EM. Coronary angioplasty versus fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003;349(22):2167-9
   PubMedGoogle Scholar
• Armstrong PW. Primary angioplasty or thrombolysis for acute myocardial infarction? Lancet 2003;361(9361):966-7
   PubMedGoogle Scholar
• Andersen HR, Nielsen TT, Rasmussen K, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003;349(8):733-42
   PubMed Web of Science ®Google Scholar
• Runge MS, Bode C, Matsueda GR, Haber E. Antibody-enhanced thrombolysis: targeting of tissue plasminogen activator in vivo. Proc Natl Acad Sci USA 1987;84(21):7659-62
   PubMed Web of Science ®Google Scholar
• Eppler S, Senn T, Gilkerson E, Modi NB. Pharmacokinetics and pharmacodynamics of recombinant tissue-type plasminogen activator following intravenous administration in rabbits: a comparison of three dosing regimens. Biopharm Drug Dispos 1998;19(1):31-8
   PubMed Web of Science ®Google Scholar
• Modi NB, Eppler S, Breed J, et al. Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction. Thromb Haemost 1998;79(1):134-9
   PubMed Web of Science ®Google Scholar
• Cohen A. Pharmacokinetics of the recombinant thrombolytic agents: what is the clinical significance of their different pharmacokinetic parameters? BioDrugs 1999;11(2):115-23
   PubMed Web of Science ®Google Scholar
• Mehvar R. Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation. J Pharm Pharm Sci 2000;3(1):125-36
   PubMed Web of Science ®Google Scholar
• Shi BZ, Mao GD, Xiong ZP. Modification of urokinase. Ann N Y Acad Sci 1988;542:180-4
   PubMedGoogle Scholar
• Lijnen HR. Fibrinolysis: molecular mechanism and pathophysiological aspects. Sangre (Barc) 1984;29(4-C):755-61
   PubMedGoogle Scholar
• Matsuo O, Bando H, Okada K, et al. Thrombolytic effect of single-chain pro-urokinase in a rabbit jugular vein thrombosis model. Thromb Res 1986;42(2):187-94
   PubMed Web of Science ®Google Scholar
• Gurewich V. Pro-urokinase: physiochemical properties and promotion of its fibrinolytic activity by urokinase and by tissue plasminogen activator with which it has a complementary mechanism of action. Semin Thromb Hemost 1988;14(1):110-5
   PubMed Web of Science ®Google Scholar
• Fletcher AP, Alkjaersing NK. Fibrinolytic and defibrinating enzymes. In: Holcenberg JS, Roberts J, editors. Enzymes as Drugs. New York, NY: John Wiley, 1981
   Google Scholar
• Brown LR. Commercial challenges of protein drug delivery. Expert Opin Drug Deliv 2005;2(1):29-42
   PubMedGoogle Scholar
• Torchilin VP. Immobilized Enzymes in Medicine. Berlin, Heildelberg: Springer-Verlag, 1991
   Google Scholar
• Torchilin VP. Targeting of thrombolytic agents: current state of knowledge and perspectives. Ann N Y Acad Sci 1992;667:404-16
   PubMed Web of Science ®Google Scholar
• Torchilin VP, Maksimenko AV, Mazaev AV. Immobilized enzymes for thrombolytic therapy. Methods Enzymol 1988;137:552-66
   PubMed Web of Science ®Google Scholar
• Torchilin VP, Maksimenko AV, Mazaev AV. Immobilized thrombolytic enzymes for systemic and local application. Ann N Y Acad Sci 1987;501:481-6
   PubMed Web of Science ®Google Scholar
• Senior JH. Fate and behavior of liposomes in vivo: a review of controlling factors. Crit Rev Ther Drug Carrier Syst 1987;3(2):123-93
   PubMed Web of Science ®Google Scholar
• Szoka F, Jr. Papahadjopoulos D. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc Natl Acad Sci USA 1978;75(9):4194-8
   PubMed Web of Science ®Google Scholar
• Papahadjopoulos D. Liposome formation and properties: an evolutionary profile. Biochem Soc Trans 1988;16(6):910-2
   PubMed Web of Science ®Google Scholar
• Lasic DD, Papahadjopoulos D, editors. Medical applications of liposomes. New York: Elsevier, 1998
   Google Scholar
• Torchilin VP, Weissig V. Liposomes : a practical approach. 2nd edition. Oxford, New York: Oxford University Press, 2003
   Google Scholar
• Gregoriadis G. Liposome technology: Liposome preparation and related techniques. 3rd edition. New York, London: Informa Healthcare, 2007
   Google Scholar
• Szoka F, Jr. Papahadjopoulos D. Comparative properties and methods of preparation of lipid vesicles (liposomes). Annu Rev Biophys Bioeng 1980;9:467-508
   PubMedGoogle Scholar
• Madden TD, Bally MB, Hope MJ, et al. Protection of large unilamellar vesicles by trehalose during dehydration: retention of vesicle contents. Biochim Biophys Acta 1985;817(1):67-74
   PubMed Web of Science ®Google Scholar
• Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett 1990;268(1):235-7
   PubMed Web of Science ®Google Scholar
• Torchilin VP, Omelyanenko VG, Papisov MI, et al. Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. Biochim Biophys Acta 1994;1195(1):11-20
   PubMed Web of Science ®Google Scholar
• Torchilin VP, Trubetskoy VS. Which polymers can make nanoparticulate drug carriers long-circulating? Adv Drug Deliv Rev 1995;16:141-55
   Web of Science ®Google Scholar
• Lukyanov AN, Gao Z, Mazzola L, Torchilin VP. Polyethylene glycol-diacyllipid micelles demonstrate increased acculumation in subcutaneous tumors in mice. Pharm Res 2002;19(10):1424-9
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Drug targeting. Eur J Pharm Sci 2000;11(Suppl 2):S81-91
   PubMed Web of Science ®Google Scholar
• Heeremans JL, Prevost R, Bekkers ME, et al. Thrombolytic treatment with tissue-type plasminogen activator (t-PA) containing liposomes in rabbits: a comparison with free t-PA. Thromb Haemost 1995;73(3):488-94
   PubMed Web of Science ®Google Scholar
• Nguyen PD, O'Rear EA, Johnson AE, et al. Accelerated thrombolysis and reperfusion in a canine model of myocardial infarction by liposomal encapsulation of streptokinase. Circ Res 1990;66(3):875-8
   PubMed Web of Science ®Google Scholar
• Weisel JW, Collet JP. Packaging is important: accelerated thrombolysis with encapsulated plasminogen activators. J Thromb Haemost 2004;2(9):1545-7
   PubMed Web of Science ®Google Scholar
• Kim IS, Choi HG, Choi HS, et al. Prolonged systemic delivery of streptokinase using liposome. Arch Pharm Res 1998;21(3):248-52
   PubMed Web of Science ®Google Scholar
• Perkins WR, Vaughan DE, Plavin SR, et al. Streptokinase entrapment in interdigitation-fusion liposomes improves thrombolysis in an experimental rabbit model. Thromb Haemost 1997;77(6):1174-8
   PubMed Web of Science ®Google Scholar
• Leach JK, O'Rear EA, Patterson E, et al. Accelerated thrombolysis in a rabbit model of carotid artery thrombosis with liposome-encapsulated and microencapsulated streptokinase. Thromb Haemost 2003;90(1):64-70
   PubMed Web of Science ®Google Scholar
• Haller CA, Cui W, Wen J, et al. Reconstitution of CD39 in liposomes amplifies nucleoside triphosphate diphosphohydrolase activity and restores thromboregulatory properties. J Vasc Surg 2006;43(4):816-23
   PubMed Web of Science ®Google Scholar
• Colletier JP, Chaize B, Winterhalter M, Fournier D. Protein encapsulation in liposomes: efficiency depends on interactions between protein and phospholipid bilayer. BMC Biotechnol 2002;10(2):9
   Google Scholar
• Weissmann G, Finkelstein M. Uptake of enzyme-bearing liposomes by cells in vivo and in vitro In: G G, C AA, eds. Liposomes in Biological Systems. New York, NY: John Wiley and Sons 1980;153-62
   Google Scholar
• Heeremans JL, Gerritsen HR, Meusen SP, et al. The preparation of tissue-type Plasminogen Activator (t-PA) containing liposomes: entrapment efficiency and ultracentrifugation damage. J Drug Target 1995;3(4):301-10
   PubMed Web of Science ®Google Scholar
• Ntimenou V, Mourtas S, Christodoulakis EV, et al. Stability of protein-encapsulating DRV liposomes after freeze-drying: A study with BSA and t-PA. J Liposome Res 2006;16(4):403-16
   PubMed Web of Science ®Google Scholar
• Khaw BA, Torchilin VP, Vural I, Narula J. Plug and seal: prevention of hypoxic cardiocyte death by sealing membrane lesions with antimyosin-liposomes. Nat Med 1995;1(11):1195-8
   PubMed Web of Science ®Google Scholar
• Bos R, Nieuwenhuizen W. The potential improvement of thrombolytic therapy by targeting with bispecific monoclonal antibodies: why they are used and how they are made. Biotherapy 1992;5(3):187-99
   PubMedGoogle Scholar
• Torchilin VP, Maksimenko AV, Tischenko EG, et al. Immobilized thrombolytic enzymes possessing increased affinity toward substrate. Ann N Y Acad Sci 1984;434:289-91
   PubMed Web of Science ®Google Scholar
• Sevilla CL, Mahle NH, Boylan CM, Callewaert DM. Plasminogen activator-anti-human fibrinogen conjugate. Biochem Biophys Res Commun 1985;130(1):91-6
   PubMed Web of Science ®Google Scholar
• Knight LC. Antifibrin antibody for detection of deep vein thrombosis. In: Khaw BA, Narula J, Strauss HW, editors. Monoclonal antibodies in cardiovascular diseases. Malvern: Lea and Febiger, 1994:171-86
   Google Scholar
• Torchilin VP. Targeting of drugs and drug carriers within the cardiovascular system. Adv Drug Deliv Rev 1995;17(1):75-102
   Web of Science ®Google Scholar
• Hui KY, Haber E, Matsueda GR. Monoclonal antibodies to a synthetic fibrin-like peptide bind to human fibrin but not fibrinogen. Science 1983;222(4628):1129-32
   PubMed Web of Science ®Google Scholar
• Hui KY, Haber E, Matsueda GR. Immunodetection of human fibrin using monoclonal antibody-64C5 in an extracorporeal chicken model. Thromb Haemost 1985;54(2):524-7
   PubMed Web of Science ®Google Scholar
• Bode C, Matsueda GR, Hui KY, Haber E. Antibody-directed urokinase: a specific fibrinolytic agent. Science 1985;229(4715):765-7
   PubMed Web of Science ®Google Scholar
• Bode C, Runge MS, Newell JB, et al. Characterization of an antibody-urokinase conjugate. A plasminogen activator targeted to fibrin. J Biol Chem 1987;262(22):10819-23
   PubMed Web of Science ®Google Scholar
• Tiukinhoy-Laing SD, Huang S, Klegerman M, et al. Ultrasound-facilitated thrombolysis using tissue-plasminogen activator-loaded echogenic liposomes. Thromb Res 2007;119(6):777-84
   PubMed Web of Science ®Google Scholar
• Bode C, Meinhardt G, Runge MS, et al. Platelet-targeted fibrinolysis enhances clot lysis and inhibits platelet aggregation. Circulation 1991;84(2):805-13
   PubMed Web of Science ®Google Scholar
• Dewerchin M, Collen D. Antiplatelet antibody-plasminogen activator conjugates for targeted thrombolysis. In: Khaw BA, Narula J, Strauss HW, editors. Monoclonal antibodies in cardiovascular diseases. Malvern: Lea and Febiger 1994:206-15
   Google Scholar
• Gupta AS, Huang G, Lestini BJ, et al. RGD-modified liposomes targeted to activated platelets as a potential vascular drug delivery system. Thromb Haemost 2005;93(1):106-14
   PubMed Web of Science ®Google Scholar
• Huang G, Zhou Z, Srinivasan R, et al. Affinity manipulation of surface-conjugated RGD peptide to modulate binding of liposomes to activated platelets. Biomaterials 2008;29(11):1676-85
   PubMed Web of Science ®Google Scholar
• Ross R. The pathogenesis of atherosclerosis: an update. N Engl J Med 1986;314(8):488-500
   PubMed Web of Science ®Google Scholar
• Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362(6423):801-9
   PubMed Web of Science ®Google Scholar
• Underwood MJ, Pringle S, de Bono DP. Reduction of thrombus formation in vivo using a thrombolytic agent targeted at damaged endothelial cells. Br J Surg 1992;79(9):915-7
   PubMed Web of Science ®Google Scholar
• Chazov EI, Alexeev AV, Antonov AS, et al. Endothelial cell culture on fibrillar collagen: model to study platelet adhesion and liposome targeting to intercellular collagen matrix. Proc Natl Acad Sci USA 1981;78(9):5603-7
   PubMed Web of Science ®Google Scholar
• Klibanov AL, Muzykantov VR, Ivanov NN, Torchilin VP. Evaluation of quantitative parameters of the interaction of antibody-bearing liposomes with target antigens. Anal Biochem 1985;150(2):251-7
   PubMed Web of Science ®Google Scholar
• Torchilin VP, Narula J, Halpern E, Khaw BA. Poly(ethylene glycol)-coated anti-cardiac myosin immunoliposomes: factors influencing targeted accumulation in the infarcted myocardium. Biochim Biophys Acta 1996;1279(1):75-83
   PubMed Web of Science ®Google Scholar
• Maksimenko AV, Torchilin VP. Water-soluble urokinase derivatives with increased affinity to the fibrin clot. Thromb Res 1985;38(3):289-95
   PubMed Web of Science ®Google Scholar
• Maksimenko AV, Samarenko MB, Petrov AD, et al. Fibrinogen-immobilized urokinase demonstrates increased thrombolytic activity in animal experiments. Ann NY Acad Sci 1990;613:479-82
   PubMed Web of Science ®Google Scholar
• Maksimenko AV, Petrov AD, Tischenko EG, Smirnov MD. Experimentally targeted thrombolytic therapy. Application of modified thrombin conjugated with urokinase. Ann NY Acad Sci 1995;750:496-501
   PubMed Web of Science ®Google Scholar
• Maksimenko AV, Rusetskii AN, Torchilin VP. [Fibrinolytic action of an enzyme preparation covalently bound to modified thrombin]. Biull Eksp Biol Med 1987;103(1):35-8
   PubMedGoogle Scholar
• Maksimenko AV, Tishvhenko EG, Petrov AD, et al. [Thrombolytic action of urokinase preparation covalently bound to modified thrombin]. Biull Eksp Biol Med 1988;106(9):322-4
   PubMedGoogle Scholar
• Meyenburg S, Lilie H, Panzner S, Rudolph R. Fibrin encapsulated liposomes as protein delivery system. Studies on the in vitro release behavior. J Control Release 2000;69(1):159-68
   PubMed Web of Science ®Google Scholar
• Khaw BA, Narula J, Kanke M, et al. Application of monoclonal antibodies in cardiovascular diseases: atherosclerosis and pulmonary emboli imaging. J Nucl Biol Med 1992;36(2 Suppl):35-40
   PubMedGoogle Scholar
• Kanke M, Matsueda GR, Strauss HW, et al. Localization and visualization of pulmonary emboli with radiolabeled fibrin-specific monoclonal antibody. J Nucl Med 1991;32(6):1254-60
   PubMed Web of Science ®Google Scholar
• Alkan-Onyuksel H, Demos SM, Lanza GM, et al. Development of inherently echogenic liposomes as an ultrasonic contrast agent. J Pharm Sci 1996;85(5):486-90
   PubMed Web of Science ®Google Scholar
• Hamilton A, Huang SL, Warnick D, et al. Left ventricular thrombus enhancement after intravenous injection of echogenic immunoliposomes: studies in a new experimental model. Circulation 2002;105(23):2772-8
   PubMed Web of Science ®Google Scholar
• Demos SM, Onyuksel H, Gilbert J, et al. In vitro targeting of antibody-conjugated echogenic liposomes for site-specific ultrasonic image enhancement. J Pharm Sci 1997;86(2):167-71
   PubMed Web of Science ®Google Scholar
• Demos SM, Dagar S, Klegerman M, et al. In vitro targeting of acoustically reflective immunoliposomes to fibrin under various flow conditions. J Drug Target 1998;5(6):507-18
   PubMed Web of Science ®Google Scholar
• Demos SM, Alkan-Onyuksel H, Kane BJ, et al. In vivo targeting of acoustically reflective liposomes for intravascular and transvascular ultrasonic enhancement. J Am Coll Cardiol 1999;33(3):867-75
   PubMed Web of Science ®Google Scholar
• Tiukinhoy-Laing SD, Buchanan K, Parikh D, et al. Fibrin targeting of tissue plasminogen activator-loaded echogenic liposomes. J Drug Target 2007;15(2):109-14
   PubMed Web of Science ®Google Scholar
• Erdogan S, Ozer AY, Bilgili H. In vivo behaviour of vesicular urokinase. Int J Pharm 2005;295(1-2):1-6
   PubMedGoogle Scholar
• Erdogan S, Ozer AY, Volkan B, et al. Thrombus localization by using streptokinase containing vesicular systems. Drug Deliv 2006;13(4):303-9
   PubMed Web of Science ®Google Scholar